| Literature DB >> 33129322 |
Yuan Zhang1,2, Miaomiao Zhang2, Xiawen Yu2, Fengjiang Wei2, Chen Chen3, Kai Zhang3, Shuzhi Feng3, Yaogang Wang1, Wei-Dong Li4.
Abstract
BACKGROUND: Hypertension and high triglyceride are two of the most important risk factors for hyperuricemia. Epidemiological records show that hypertension and dyslipidemia often coexist and may significantly increase the risk of target organ damage. However, their combined effect on incident hyperuricemia is poorly understood. Thus, we aimed to investigate the separate and combined effect of hypertension and hypertriglyceridemia on the incidence of hyperuricemia.Entities:
Keywords: Hypertension; Hypertriglyceridemia; Hyperuricemia; Prospective cohort study
Mesh:
Year: 2020 PMID: 33129322 PMCID: PMC7603698 DOI: 10.1186/s12967-020-02590-8
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Baseline characteristics of subjects by combining hypertension and hypertriglyceridemia status
| Variables | Normotension and normal TG | Hypertension and normal TG | Normotension and HTG | Hypertension and HTG | |
|---|---|---|---|---|---|
| 2515 (39.2) | 2028 (31.6) | 907 (14.1) | 974 (15.2) | ||
| Age (years) | 57.3 ± 13.5 | 68.4 ± 12.5 | 56.8 ± 11.6 | 64.1 ± 12.4 | < 0.001 |
| Men (%) | 1704 (67.8) | 1659 (81.8) | 711 (78.4) | 974 (79.8) | < 0.001 |
| TG (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.3 | 2.6 ± 1.3 | 2.6 ± 1.3 | < 0.001 |
| TC (mmol/L) | 4.7 ± 0.8 | 4.8 ± 0.8 | 5.1 ± 0.9 | 5.1 ± 0.9 | < 0.001 |
| FPG (mmol/L) | 5.1 ± 0.9 | 5.5 ± 1.3 | 5.3 ± 1.4 | 5.7 ± 1.7 | < 0.001 |
| SBP (mmHg) | 120.9 ± 11.1 | 153.8 ± 19.9 | 123.0 ± 10.6 | 152.6 ± 14.4 | < 0.001 |
| DBP (mmHg) | 69.8 ± 8.7 | 81.7 ± 11.8 | 72.5 ± 8.5 | 84.6 ± 12.0 | < 0.001 |
| SUA (µmol/L) | 298.0 ± 60.9 | 308.6 ± 60.7 | 325.1 ± 56.1 | 332.5 ± 55.9 | < 0.001 |
| BUN (mmol/L) | 5.1 ± 1.3 | 5.4 ± 1.3 | 5.1 ± 1.2 | 5.3 ± 1.2 | < 0.001 |
| SCR (µmol/L) | 75.8 ± 15.7 | 81.3 ± 17.1 | 78.7 ± 14.1 | 81.4 ± 16.3 | < 0.001 |
| eGFR (ml/min/1.73 m2) | 92.9 ± 18.3 | 86.4 ± 19.6 | 91.3 ± 16.6 | 86.8 ± 18.0 | < 0.001 |
| proteinuria (%) | 62 (2.5) | 80 (3.9) | 33 (3.6) | 53 (5.4) | < 0.001 |
| TP (g/L) | 73.4 ± 3.9 | 74.3 ± 4.3 | 74.7 ± 4.0 | 75.8 ± 4.1 | < 0.001 |
| ALT (IU/L) | 21.2 ± 12.4 | 21.8 ± 12.8 | 26.4 ± 12.2 | 27.4 ± 16.0 | < 0.001 |
| TBIL (µmol/L) | 13.7 ± 5.3 | 14.1 ± 5.0 | 13.3 ± 4.6 | 13.6 ± 4.4 | 0.057 |
| BMI (kg/m2) | 23.5 ± 2.9 | 24.8 ± 3.1 | 25.0 ± 2.7 | 26.1 ± 2.8 | < 0.001 |
TG plasma triglyceride level, TC total cholesterol, FPG fasting plasma glucose, SBP systolic blood pressure, DBP diastolic blood pressure, SUA serum uric acid, BUN blood urea nitrogen, SCR serum creatinine, eGFR estimated glomerular filtration rate, TP plasma total protein, ALT alanine aminotransferase, TBIL total bilirubin, BMI body mass index, HTG hypertriglyceridemia
*P < 0.05 was considered statistically significant
Hazard ratio for the incidence of hyperuricemia by combining hypertension and hypertriglyceridemia status
| Hazard Ratio (95% | |||||
|---|---|---|---|---|---|
| Normotension and normal TG | Hypertension and normal TG | Normotension and HTG | Hypertension and HTG | ||
| Overalla | |||||
| Model 1 | 1 (Ref.) | 1.48 (1.28–1.71) | 1.84 (1.55–2.18) | 3.02 (2.60–3.50) | < 0.001 |
| Model 2 | 1 (Ref.) | 1.39 (1.19–1.63) | 1.80 (1.52–2.14) | 2.88 (2.48–3.36) | < 0.001 |
| Model 3 | 1 (Ref.) | 1.24 (1.05–1.46) | 1.61 (1.34–1.93) | 2.36 (2.00–2.78) | < 0.001 |
| Menb | |||||
| Model 1 | 1 (Ref.) | 1.28 (1.09–1.52) | 1.58 (1.30–1.91) | 2.63 (2.23–3.11) | < 0.001 |
| Model 2 | 1 (Ref.) | 1.28 (1.08–1.51) | 1.57 (1.29–1.91) | 2.63 (2.22–3.11) | < 0.001 |
| Model 3 | 1 (Ref.) | 1.17 (0.98–1.40) | 1.43 (1.17–1.76) | 2.22 (1.85–2.67) | < 0.001 |
| Womenb | |||||
| Model 1 | 1 (Ref.) | 2.06 (1.48–2.87) | 2.77 (1.93–3.98) | 4.16 (3.00–5.76) | < 0.001 |
| Model 2 | 1 (Ref.) | 1.77 (1.23–2.56) | 2.62 (1.82–3.78) | 3.60 (2.52–5.16) | < 0.001 |
| Model 3 | 1 (Ref.) | 1.57 (1.07–2.32) | 2.36 (1.60–3.47) | 2.76 (1.87–4.07) | < 0.001 |
aModel 1 was unadjusted baseline values of variables. Model 2 was adjustment for age and sex. Model 3 was further adjustment for body-mass index, eGFR, blood urea nitrogen and proteinuria
bModel 1 was unadjusted baseline values of variables. Model 2 was adjustment for age. Model 3 was further adjustment for body-mass index, eGFR, blood urea nitrogen and proteinuria
Fig. 1Kaplan‑Meier curves for the incidence of hyperuricemia among four groups in overall (a); in men (b), and in women (c). (log‑rank test P-value < 0.05, HTN + HTG group vs. other groups). Normal, normotension and normal triglyceride; HTN, hypertension and normal triglyceride; HTG: normotension and hypertriglyceridemia; HTN + HTG, hypertension and hypertriglyceridemia
Stratified Analysis of multivariate hazard ratios for hyperuricemia among 6424 individuals according to combining hypertension and hypertriglyceridemia status
| Hazard Ratio (95% | ||||||
|---|---|---|---|---|---|---|
| Normotension and normal TG | Hypertension | Normotension and | Hypertension | |||
| Body-mass index | ||||||
| < 24 | 1 | 1.46 (1.12–1.92) | 1.96 (1.45–2.64) | 2.49 (1.81–3.44) | < 0.001 | 0.80 |
| 24 ~ 27.9 | 1 | 1.16 (0.92–1.47) | 1.51 (1.17–1.95) | 2.24 (1.79–2.82) | < 0.001 | |
| ≥ 28 | 1 | 1.06 (0.68–1.66) | 1.30 (0.78–2.17) | 2.40 (1.58–3.66) | < 0.001 | |
| eGFR (ml/min/1.73 m2) | 0.60 | |||||
| < 60 | 1 | 1.17 (0.37–3.78) | 1.70 (0.75–3.86) | 3.63 (1.58–5.33) | < 0.001 | |
| ≥ 60 | 1 | 1.24 (1.04–1.48) | 1.65 (1.37–2.00) | 2.34 (1.96–2.78) | < 0.001 | |
The Cox regression analysis was adjusted, if not stratified, for age, body-mass index, and blood urea nitrogen, as continuous variables; eGFR (< 60 or ≥ 60 ml/min/1.73 m2 or missing information); and proteinuria (positive, negative, or missing information)
Fig. 2Receiver operating characteristic (ROC) curve for the prediction of hyperuricemia from blood pressure combined with TG levels in overall (a); in men (b), and in women (c). AUC, area under the curve. All models AUC > 0.500, P < 0.001